Asia Pacific Cannabis Pharmaceuticals Market Size & Outlook
Asia Pacific cannabis pharmaceuticals market, 2018-2030 (US$M)
Related Markets
Asia Pacific cannabis pharmaceuticals market highlights
- The Asia Pacific cannabis pharmaceuticals market generated a revenue of USD 276.7 million in 2023.
- The market is expected to grow at a CAGR of 64.2% from 2024 to 2030.
- In terms of segment, other brands was the largest revenue generating brand type in 2023.
- Other Brands is the most lucrative brand type segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 276.7 million |
| Market revenue in 2030 | USD 8,888.7 million |
| Growth rate | 64.2% (CAGR from 2023 to 2030) |
| Largest segment | Other brands |
| Fastest growing segment | Other Brands |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sativex, Epidiolex, Other Brands |
| Key market players worldwide | Jazz Pharmaceuticals PLC, AbbVie Inc, Insys Therapeutics, Bausch Health Companies Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 8.1% of the global cannabis pharmaceuticals market in 2023.
- Globally, Latin America is projected to lead the regional market in terms of revenue in 2030.
- Latin America is the fastest growing regional market and is projected to reach USD 33,621.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cannabis Pharmaceuticals Market Scope
Cannabis Pharmaceuticals Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cannabis pharmaceuticals market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cannabis pharmaceuticals market will help companies and investors design strategic landscapes.
Other brands was the largest segment with a revenue share of 50.42% in 2023. Horizon Databook has segmented the Asia Pacific cannabis pharmaceuticals market based on sativex, epidiolex, other brands covering the revenue growth of each sub-segment from 2018 to 2030.
Growing awareness regarding the benefits provided by cannabis-based pharmaceuticals on certain medical conditions, such as tuberous sclerosis complex, cancer, chronic pain, epilepsy, and multiple sclerosis, is anticipated to boost market growth in the coming years.
In addition, the rising number of clinical studies demonstrating the positive effects of cannabis pharmaceuticals and the increasing number of countries in the region allowing the use of cannabis-based pharmaceuticals are among the factors propelling the market growth in the region.
Reasons to subscribe to Asia Pacific cannabis pharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific cannabis pharmaceuticals market databook
-
Our clientele includes a mix of cannabis pharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cannabis pharmaceuticals market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cannabis pharmaceuticals market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific cannabis pharmaceuticals market size, by country, 2018-2030 (US$M)
Asia Pacific Cannabis Pharmaceuticals Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
